Semaglutide treats liver disease in two thirds of patients

Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine shows treating patients with the substance can halt and even reverse the disease.

The placebo-controlled outcome trial of participants with a life-threatening form of liver disease known as Metabolic dysfunction associated steatohepatitis (MASH) was conducted at 253 clinical sites across 37…